FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileDermata Therapeutics, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
DRMAW
Dermata Therapeutics, Inc. Stock AnalysisComprehensive stock analysis for Dermata Therapeutics, Inc. (DRMAW) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisDRMAW
DRMAW
Dermata Therapeutics, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
DRMAW
  1. Home
  2. Stocks
  3. Dermata Therapeutics, Inc.

Dermata Therapeutics, Inc.

🇺🇸DRMAW•NASDAQ

Dermata Therapeutics, Inc.

🇺🇸DRMAW•NASDAQ
Market cap
$409

Your view on DRMAW

Mkt Cap
$409
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Dermata Therapeutics, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Gerald T. Proehl
Headquarters
3525 Del Mar Heights Road, San Diego, CA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Gerald T. Proehl
Headquarters
3525 Del Mar Heights Road, San Diego, CA, US
Description

Dermata Therapeutics, Inc., a biotechnology company in the clinical development stage, is headquartered in San Diego, California, and was established in 2014. The firm's core mission is to develop innovative treatments for a variety of dermatological and cosmetic skin conditions.

Its flagship investigational product, DMT310, is a topical formula applied once weekly that is currently undergoing clinical trials. This primary compound is being evaluated for its effectiveness against acne vulgaris, psoriasis vulgaris, and papulopustular rosacea.

Additionally, the company is advancing DMT410, which is intended to address hyperhidrosis (excessive sweating) and other aesthetic concerns.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Dermata Therapeutics, Inc.. Starting points for Dermata Therapeutics, Inc.: EPS -$1476.80, beta 0.66 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Dermata Therapeutics, Inc.. Trailing twelve-month EPS for Dermata Therapeutics, Inc. stands at -$1476.80. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 20, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Earnings Estimate

EPSCurrent QtrDec 2026Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate−$0.56−$2.21−$1.52
Low estimate−$0.56−$2.21−$1.52
High estimate−$0.56−$2.21−$1.52
No. of analysts111
Year-ago EPS−$1.52−$8.16—
Growth+63.2%+72.9%—

Revenue Estimate

RevenueCurrent QtrDec 2026Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$75000.00$100000.00$750000.00
Low estimate$75000.00$100000.00$750000.00
High estimate$75000.00$100000.00$750000.00
No. of analysts111
Year-ago revenue$0.00$0.00—
Growth———

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 20, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Dermata Therapeutics, Inc.. Dermata Therapeutics, Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold DRMAW20 companies
Compare DRMAW with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
AKTXAkari Therapeutics, PlcHealthcareBiotechnology$15.3M
CDTCDT Equity Inc.HealthcareBiotechnology$159,886
FOXOFOXO Technologies Inc.HealthcareMedical - Care Facilities$8,997
PIIIP3 Health Partners Inc.HealthcareMedical - Care Facilities$7.0M
PPBTPurple Biotech Ltd.HealthcareBiotechnology$236,124
REVBRevelation Biosciences, Inc.HealthcareBiotechnology$2.2M
SLXNWSilexion Therapeutics Ltd.HealthcareBiotechnology$42,542
SYRSSyros Pharmaceuticals, Inc.HealthcareBiotechnology$21,464
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
BCLIBrainstorm Cell Therapeutics Inc.HealthcareOTC$6.8M
BCRXBioCryst Pharmaceuticals, Inc.HealthcareNASDAQ$1.9B
BCT.TOBriaCell Therapeutics Corp.HealthcareTSX$40.6M
BCTXBriaCell Therapeutics Corp.HealthcareNASDAQ$28.6M
BCTXZBriaCell Therapeutics Corp. WarrantHealthcareNASDAQ$239,235
BCYCBicycle Therapeutics plcHealthcareNASDAQ$218.0M
BDRXBiodexa Pharmaceuticals PlcHealthcareNASDAQ$189,830
BDTXBlack Diamond Therapeutics, Inc.HealthcareNASDAQ$82.2M
BEAMBeam Therapeutics Inc.HealthcareNASDAQ$2.2B
BETR.CNBetterLife Pharma Inc.HealthcareCNQ—
BETRFBetterLife Pharma Inc.HealthcareOTC$6.4M
BHVNBiohaven Ltd.HealthcareNYSE$1.9B
Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Dermata Therapeutics, Inc., and how their positions are changing. At a $409 market value, institutional positions materially move Dermata Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Dermata Therapeutics, Inc. executives and directors. Shares of Dermata Therapeutics, Inc. have traded between $0.0066 and $0.02 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Dermata Therapeutics, Inc.. Coverage tracks Dermata Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Dermata Therapeutics, Inc.

DRMAW AnalysisFair
Past
1
Growth
2
Health
5
Profit
1
Value
1

News

Latest Market News